Aloe Blacc's fame means nothing in biotech (and that's the point) | TechCrunch

"Aloe Blacc found that you can't just write a check in biotech; regulators require a commercialization plan, and philanthropy doesn't advance science through clinical trials."

"He is bootstrapping a cancer drug platform targeting pancreatic cancer, a disease that kills 90% of its patients, and is waiting for peer-reviewed papers to support his case."

"Blacc is observing how AI is reshaping both the biotech and music industries in real time, reflecting on the implications for creators and investors."

Aloe Blacc contracted COVID despite being vaccinated and sought to fund biotech research. He discovered that philanthropy alone cannot advance science through clinical trials. Regulations necessitate a commercialization plan. Consequently, he is now developing a cancer drug platform targeting pancreatic cancer, which has a high mortality rate. Blacc plans to wait for peer-reviewed research to support his funding efforts. He also discusses the impact of AI on both the biotech and music industries.

Read at TechCrunch